These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 36372278

  • 1. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO, Glotfelty EJ, Li Y, Greig NH.
    Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
    [Abstract] [Full Text] [Related]

  • 2. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
    Kopp KO, Li Y, Glotfelty EJ, Tweedie D, Greig NH.
    Biomolecules; 2024 Jul 19; 14(7):. PubMed ID: 39062586
    [Abstract] [Full Text] [Related]

  • 3. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
    Ferrari F, Moretti A, Villa RF.
    Pharmacol Ther; 2022 Nov 19; 239():108277. PubMed ID: 36064147
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH.
    Expert Opin Investig Drugs; 2020 Jun 19; 29(6):595-602. PubMed ID: 32412796
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
    Hölscher C.
    Br J Pharmacol; 2022 Feb 19; 179(4):695-714. PubMed ID: 33900631
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases.
    Li Y, Li L, Hölscher C.
    Rev Neurosci; 2016 Oct 01; 27(7):689-711. PubMed ID: 27276528
    [Abstract] [Full Text] [Related]

  • 11. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA, Bergmann NC, Knop FK.
    Diabetes Obes Metab; 2016 Sep 01; 18(9):847-54. PubMed ID: 27160961
    [Abstract] [Full Text] [Related]

  • 12. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C.
    Expert Opin Investig Drugs; 2020 Apr 01; 29(4):333-348. PubMed ID: 32175781
    [Abstract] [Full Text] [Related]

  • 13. Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
    Kopp KO, Glotfelty EJ, Li Y, Lahiri DK, Greig NH.
    Ageing Res Rev; 2024 Jul 01; 98():102343. PubMed ID: 38762101
    [Abstract] [Full Text] [Related]

  • 14. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ, Tenenbaum A.
    Cardiovasc Diabetol; 2021 Nov 24; 20(1):225. PubMed ID: 34819089
    [Abstract] [Full Text] [Related]

  • 15. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Sheng Li Xue Bao; 2014 Oct 25; 66(5):497-510. PubMed ID: 25331995
    [Abstract] [Full Text] [Related]

  • 16. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.
    Diz-Chaves Y, Mastoor Z, Spuch C, González-Matías LC, Mallo F.
    Int J Mol Sci; 2022 Aug 24; 23(17):. PubMed ID: 36076972
    [Abstract] [Full Text] [Related]

  • 17. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C.
    Recent Pat CNS Drug Discov; 2010 Jun 24; 5(2):109-17. PubMed ID: 20337586
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
    Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C.
    Expert Opin Ther Targets; 2022 May 24; 26(5):445-460. PubMed ID: 35584372
    [Abstract] [Full Text] [Related]

  • 19. Incretin hormones and type 2 diabetes.
    Nauck MA, Müller TD.
    Diabetologia; 2023 Oct 24; 66(10):1780-1795. PubMed ID: 37430117
    [Abstract] [Full Text] [Related]

  • 20. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q, Akindehin SE, Orsso CE, Waldner RC, DiMarchi RD, Müller TD, Haqq AM.
    Front Endocrinol (Lausanne); 2022 Oct 24; 13():838410. PubMed ID: 35299971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.